A phase I study of CHOP [cyclophosphamide, vincristine, doxorubicin, prednisone] and Campath-1H [alemtuzumab] in previously untreated aggressive T/NK-Cell lymphomas.

Trial Profile

A phase I study of CHOP [cyclophosphamide, vincristine, doxorubicin, prednisone] and Campath-1H [alemtuzumab] in previously untreated aggressive T/NK-Cell lymphomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
  • Indications Diffuse large B cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2013 Planned end date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Planned End Date changed from 1 May 2008 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top